The U.S. Food and Drug Administration has granted priority review to Gilead Sciences’ New Drug Application for a fixed-dose, single-tablet regimen combining bictegravir (75 mg) and lenacapavir (50 mg) for the treatment of HIV-1 infection in virologically suppressed adults. The agency assigned a PDUFA action date of August 27, 2026, setting up a potential approval decision later this northern summer.

The NDA is supported by two Phase 3 trials. ARTISTRY-1 and ARTISTRY-2 evaluated the safety and efficacy of switching virologically suppressed adults from their current antiretroviral regimen to once-daily BIC/LEN. ARTISTRY-1 primary results were published in The Lancet on February 25, 2026, and demonstrated that BIC/LEN maintained virological suppression non-inferiorly to continuing background regimens in patients with documented treatment complexity or intolerance to prior therapy. ARTISTRY-2 confirmed those findings in a broader population of virologically stable adults regardless of prior regimen complexity.

Lenacapavir, already approved as Sunlenca for heavily treatment-experienced patients, acts by disrupting HIV-1 capsid function at multiple stages of the viral lifecycle, including nuclear import, integration, and new capsid assembly. Bictegravir, the active integrase strand transfer inhibitor in Biktarvy (Gilead’s existing blockbuster regimen), inhibits integrase activity with a high genetic barrier to resistance. Combining two mechanistically distinct agents with complementary resistance profiles into a once-daily tablet addresses a longstanding clinical objective: simplification without compromise in antiviral potency.

The clinical significance of this combination extends beyond convenience. For patients who have developed intolerance to tenofovir-based or abacavir-based backbone agents, the BIC/LEN tablet offers a nucleoside reverse transcriptase inhibitor-free option, a category of HIV therapy with growing clinical interest particularly for patients with renal impairment or reduced bone mineral density.

Priority review designation typically applies to therapies offering substantial improvement over available therapy. The FDA’s decision to grant priority review acknowledges that BIC/LEN occupies a clinically meaningful niche, even in a crowded HIV treatment landscape that already includes Biktarvy, Dovato, and Cabenuva.

The global HIV treatment market exceeds USD 28 billion annually. If approved, BIC/LEN would compete directly with Gilead’s own Biktarvy, a USD 13-billion-per-year product, raising the question of how the company manages lifecycle extension versus cannibalisation. Analysts have suggested that BIC/LEN’s primary commercial opportunity lies in treatment-experienced patients and those cycling off nucleoside backbone therapies, rather than naive initiators where Biktarvy retains a strong foothold.